Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
about
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CAPhase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.Targeted therapy in melanoma.Antivascular therapy for epithelial ovarian cancer.Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma.Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.Nutlin-3 enhances sorafenib efficacy in renal cell carcinomaTargeted therapies for gastric cancer: current status.Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 AmplificationClinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.An interim safety analysis of hepatocellular carcinoma patients administrating oral vitamin K with or without sorafenib.Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma.Targeting angiogenesis in metastatic breast cancerSynergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.How many diseases are colorectal cancer?Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary studySorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic responsePolyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.Combined therapeutic efficacy of (188)Re-liposomes and sorafenib in an experimental colorectal cancer liver metastasis model by intrasplenic injection of C26-luc murine colon cancer cells.Sorafenib in locally advanced or metastatic breast cancer.Sorafenib for ovarian cancer.Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?Sorafenib: 10 years after the first pivotal trial.Antitumor and antimetastasis effects of carboplatin liposomes with polyethylene glycol-2000 on SGC-7901 gastric cell-bearing nude mice.Combination therapy using oral S-1 and targeted agents against human tumor xenografts in nude mice.Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.Sorafenib for the treatment of hepatocellular carcinoma across geographic regions.Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.The in vivo antitumor effects of type I-interferon against hepatocellular carcinoma: the suppression of tumor cell growth and angiogenesis.Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell linesSorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells.Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.Isobavachalcone sensitizes cells to E2-induced paclitaxel resistance by down-regulating CD44 expression in ER+ breast cancer cells
P2860
Q30528973-660EA89F-3544-4805-B603-C19F6D551ADBQ33414998-9003AF89-A4D2-4D08-9002-D7B2FD25FB8CQ33415840-9D44EF5F-B438-4C0A-91B3-FBBE80B874C0Q33573107-DFF97F2D-E90B-41F8-A228-3E1871E52DCCQ33583598-C78F53B4-43FF-4552-9846-2E56718205FBQ33620083-378E5A7C-F70F-4382-AD34-8C48F4CC715DQ33686690-AD92E264-A1BD-498D-AD6D-9477E922E45EQ33702040-E797B645-4259-4544-90FC-75429CFFBDF5Q34008781-0D9CCC45-A802-466E-8365-33532FAB56C0Q34127380-8A693069-4AD2-4280-A80B-4A1D94A9B1A6Q34205672-1B1138ED-7EA1-4A4F-BFA1-443CFE22CBE0Q35128289-0E5D1560-DD95-468D-B08E-9A73BD7B2835Q35183062-77AC9934-204E-4159-9503-9CC10D7CD82FQ35599769-DA45A523-D9CA-4AD0-A609-C6D18EFD2DDFQ35826293-402255FC-D338-4C5A-8AF6-30DCD6632EF4Q36010837-E4D25DBE-B7B1-4645-AE83-BF0DED8B967FQ36084341-193B3B9A-6E05-449F-BCE1-6C6CB03EFF65Q36182795-BAC92E58-977F-4551-A32C-380166690893Q36185717-CE137B8E-62A1-4C60-BC70-EB801ED5F65AQ36223025-DF5E77B9-F842-438F-8A28-D60A8F1639D2Q36238965-82B358D4-0352-47C8-93A4-33D172AF4348Q36493616-238945AF-0B97-4085-8E7D-AD301FF6C015Q36524239-BC33D6EF-02FC-425E-AAA2-E128F2A3BC50Q37669173-DBCA319F-AC83-4022-B9FC-6F92FC77C75CQ37722142-34988929-66C9-4322-95C4-D9AEE5BEB94AQ38012156-E6962B21-CCDE-4258-8970-5AFB9F918663Q38106994-D3E5DBC4-17B9-4D02-A730-F1EE984E142EQ38322346-7E2CA8E9-1894-4667-8C5A-931E85EACF30Q38544841-5703C296-8A6F-4A00-BDCE-59C3F1B66EC2Q38949763-A93173D7-AB9F-4A25-ACDD-3ED797A7F43CQ39280635-83AB43D6-1FAC-4404-8113-0D6F49AD942EQ39511381-49EB7A15-DF2A-42ED-9708-00BA21F79F0FQ39843822-22398217-D01D-4202-9FC1-D228C3247ACAQ39998919-F61CE133-B06B-4C39-94AF-A1023C155418Q41651606-F79920A4-B13C-42B1-BCE1-1E74E647E675Q41841187-8F917353-08FA-433E-BBCF-C93394AA6C18Q41969486-41BD5B8B-2C4A-49A5-BABF-FD7990BDC4CBQ42416897-3BD0D144-BD1E-41B2-9B7D-CBB936E81869Q48345914-0CA09E03-2AE7-47F4-8F24-479C66D226E7Q58764017-EB4B4790-C21B-4749-968B-A3451851D14D
P2860
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Selected combination therapy w ...... ives in advanced solid tumors.
@ast
Selected combination therapy w ...... ives in advanced solid tumors.
@en
type
label
Selected combination therapy w ...... ives in advanced solid tumors.
@ast
Selected combination therapy w ...... ives in advanced solid tumors.
@en
prefLabel
Selected combination therapy w ...... ives in advanced solid tumors.
@ast
Selected combination therapy w ...... ives in advanced solid tumors.
@en
P1433
P1476
Selected combination therapy w ...... tives in advanced solid tumors
@en
P2093
Ahmad Awada
Lissandra Dal Lago
P304
P356
10.1634/THEONCOLOGIST.2007-0233
P577
2008-08-11T00:00:00Z